National Securities Corporation initiated coverage on Oramed Pharmaceuticals with a new price target

2/9/21 10:55:21 AM ET

Biotechnology: Pharmaceutical Preparations

Health Care

National Securities Corporation initiated coverage of Oramed Pharmaceuticals with a rating of Buy and set a new price target of $23.00

Save time and jump to the most important pieces.

Recent Analyst Ratings for
$ORMP

Date	Price Target	Rating	Analyst
1/12/2023	$30.00 → $3.00	Buy → Hold	Canaccord Genuity
2/18/2022	$20.00	Overweight	Cantor Fitzgerald
11/30/2021	$17.00 → $32.00	Buy	HC Wainwright & Co.
11/29/2021	$17.00 → $32.00	Buy	HC Wainwright & Co.
11/2/2021	$20.00 → $35.00	Buy	Aegis Capital
7/29/2021	$27.00 → $30.00	Buy	Canaccord Genuity